Enveric Biosciences Inc (ENVB)

$2.95 +0.04 (1.37%)
Market Cap 1.74M
Revenue (ttm) 0.00
Net Income (ttm) -9.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 24,300
Avg Vol 857,072
Day's Range N/A - N/A
Shares Out 597,000.00
Stochastic %K 10%
Beta 0.30
Analysts Strong Buy
Price Target $10.00

Company Profile

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. It also focuses on the development of cannabinoid conjugate molecules...

Industry: Biotechnology
Sector: Healthcare
Address:
245 First Street, Riverview II 18 th Floor, Cambridge, United States
cashcow1
cashcow1 Feb. 3 at 11:26 PM
$ENVB when will this bounce? Volume is low
0 · Reply
cashcow1
cashcow1 Feb. 3 at 1:28 AM
$ENVB any hope?
1 · Reply
RBLUCKY
RBLUCKY Jan. 31 at 5:50 AM
$ENVB
0 · Reply
Luckyjs38
Luckyjs38 Jan. 30 at 7:00 PM
$RPGL $TCGL $AMC $GME $ENVB
0 · Reply
Luckyjs38
Luckyjs38 Jan. 30 at 5:38 PM
$RPGL $TCGL $AMC $GME $ENVB
0 · Reply
Luckyjs38
Luckyjs38 Jan. 30 at 5:31 PM
$RPGL $TCGL $AMC $GME $ENVB if you know you know Hold
0 · Reply
Luckyjs38
Luckyjs38 Jan. 30 at 3:31 PM
$TCGL up next $ENVB 🔮🐦‍🔥
0 · Reply
cashcow1
cashcow1 Jan. 29 at 10:05 PM
$ENVB will this bounce?
1 · Reply
FUAD197523
FUAD197523 Jan. 29 at 8:12 PM
$ENVB You son of a bitch
1 · Reply
johnnylawrencecobra
johnnylawrencecobra Jan. 29 at 5:41 PM
$ENVB I bought 8,500 today QB
0 · Reply
Latest News on ENVB
Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option

Jan 29, 2026, 8:00 AM EST - 5 days ago

Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option

Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Jan 28, 2026, 5:00 PM EST - 6 days ago

Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Jan 28, 2026, 8:00 AM EST - 6 days ago

Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Enveric Biosciences Announces Patent Issuance

Dec 29, 2025, 8:00 AM EST - 5 weeks ago

Enveric Biosciences Announces Patent Issuance

Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds

Dec 12, 2025, 4:46 PM EST - 7 weeks ago

Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds

Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds

Dec 11, 2025, 1:43 PM EST - 7 weeks ago

Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds

Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates

Dec 9, 2025, 8:00 AM EST - 2 months ago

Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2026”

Dec 4, 2025, 8:00 AM EST - 2 months ago

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2026”

Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates

Nov 26, 2025, 8:00 AM EST - 2 months ago

Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates

Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results

Nov 14, 2025, 4:05 PM EST - 2 months ago

Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results

Enveric Biosciences Announces Reverse Stock Split

Oct 23, 2025, 8:00 AM EDT - 3 months ago

Enveric Biosciences Announces Reverse Stock Split

Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance

Oct 16, 2025, 8:30 AM EDT - 3 months ago

Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance

Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal

Oct 15, 2025, 8:00 AM EDT - 3 months ago

Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal

Enveric Biosciences to Explore Digital Asset Treasury Opportunities

Oct 14, 2025, 9:00 AM EDT - 4 months ago

Enveric Biosciences to Explore Digital Asset Treasury Opportunities

Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials

Oct 2, 2025, 8:45 AM EDT - 4 months ago

Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials

Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Sep 18, 2025, 4:30 PM EDT - 4 months ago

Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Sep 17, 2025, 9:24 AM EDT - 4 months ago

Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery

Sep 17, 2025, 8:00 AM EDT - 4 months ago

Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery

Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission

Sep 16, 2025, 8:45 AM EDT - 5 months ago

Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission

Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:30 AM EDT - 5 months ago

Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference

Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA

Sep 2, 2025, 8:30 AM EDT - 5 months ago

Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA

Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications

Aug 28, 2025, 8:30 AM EDT - 5 months ago

Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications

Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results

Aug 14, 2025, 8:00 AM EDT - 6 months ago

Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results

Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

Jul 23, 2025, 8:03 AM EDT - 6 months ago

Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)

Jul 15, 2025, 9:03 AM EDT - 7 months ago

Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)

Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003

Jun 24, 2025, 9:03 AM EDT - 8 months ago

Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003

Enveric Biosciences Announces Participation in 2025 BIO International Convention

Jun 16, 2025, 10:46 AM EDT - 8 months ago

Enveric Biosciences Announces Participation in 2025 BIO International Convention

Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

Jun 10, 2025, 9:03 AM EDT - 8 months ago

Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds

Jun 3, 2025, 9:00 AM EDT - 8 months ago

Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds

Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003

May 28, 2025, 9:03 AM EDT - 8 months ago

Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003

Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease

May 20, 2025, 8:00 AM EDT - 9 months ago

Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease

Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results

May 14, 2025, 4:15 PM EDT - 9 months ago

Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024

Mar 31, 2025, 8:00 AM EDT - 11 months ago

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024

Enveric Biosciences Participating in BIO-Europe Spring®

Mar 17, 2025, 1:40 PM EDT - 11 months ago

Enveric Biosciences Participating in BIO-Europe Spring®

Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark

Mar 6, 2025, 10:00 AM EST - 11 months ago

Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark

Enveric Biosciences CEO Issues Letter to Shareholders

Feb 27, 2025, 9:30 AM EST - 1 year ago

Enveric Biosciences CEO Issues Letter to Shareholders

Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent

Feb 25, 2025, 1:30 PM EST - 1 year ago

Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent

Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease

Feb 4, 2025, 8:00 AM EST - 1 year ago

Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease

Enveric Biosciences Announces Closing of $5 Million Public Offering

Feb 3, 2025, 5:00 PM EST - 1 year ago

Enveric Biosciences Announces Closing of $5 Million Public Offering

Enveric Biosciences Announces Pricing of $5 Million Public Offering

Jan 30, 2025, 8:14 PM EST - 1 year ago

Enveric Biosciences Announces Pricing of $5 Million Public Offering

Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office

Jan 30, 2025, 4:01 PM EST - 1 year ago

Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025”

Jan 6, 2025, 8:30 AM EST - 1 year ago

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025”

Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds

Dec 2, 2024, 8:00 AM EST - 1 year ago

Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds

Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior

Nov 25, 2024, 9:00 AM EST - 1 year ago

Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior

Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results

Nov 14, 2024, 4:05 PM EST - 1 year ago

Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results

Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002

Nov 12, 2024, 9:00 AM EST - 1 year ago

Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002

Enveric Biosciences Announces Broad Range of Patent Issuances

Nov 4, 2024, 10:36 AM EST - 1 year ago

Enveric Biosciences Announces Broad Range of Patent Issuances

Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003

Oct 15, 2024, 8:00 AM EDT - 1 year ago

Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003

Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop

Sep 26, 2024, 8:30 AM EDT - 1 year ago

Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop

Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit

Sep 25, 2024, 8:30 AM EDT - 1 year ago

Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit

cashcow1
cashcow1 Feb. 3 at 11:26 PM
$ENVB when will this bounce? Volume is low
0 · Reply
cashcow1
cashcow1 Feb. 3 at 1:28 AM
$ENVB any hope?
1 · Reply
RBLUCKY
RBLUCKY Jan. 31 at 5:50 AM
$ENVB
0 · Reply
Luckyjs38
Luckyjs38 Jan. 30 at 7:00 PM
$RPGL $TCGL $AMC $GME $ENVB
0 · Reply
Luckyjs38
Luckyjs38 Jan. 30 at 5:38 PM
$RPGL $TCGL $AMC $GME $ENVB
0 · Reply
Luckyjs38
Luckyjs38 Jan. 30 at 5:31 PM
$RPGL $TCGL $AMC $GME $ENVB if you know you know Hold
0 · Reply
Luckyjs38
Luckyjs38 Jan. 30 at 3:31 PM
$TCGL up next $ENVB 🔮🐦‍🔥
0 · Reply
cashcow1
cashcow1 Jan. 29 at 10:05 PM
$ENVB will this bounce?
1 · Reply
FUAD197523
FUAD197523 Jan. 29 at 8:12 PM
$ENVB You son of a bitch
1 · Reply
johnnylawrencecobra
johnnylawrencecobra Jan. 29 at 5:41 PM
$ENVB I bought 8,500 today QB
0 · Reply
FUAD197523
FUAD197523 Jan. 29 at 4:57 PM
$ENVB You son of a bitch
0 · Reply
Luckyjs38
Luckyjs38 Jan. 29 at 4:34 PM
$ENVB
0 · Reply
Luckyjs38
Luckyjs38 Jan. 29 at 4:33 PM
$SPY $IWM $QQQ $ENVB
0 · Reply
RedDogSailor
RedDogSailor Jan. 29 at 1:25 PM
$ENVB That’s great news AND the offering is closed.
0 · Reply
Luckyjs38
Luckyjs38 Jan. 29 at 1:20 PM
$SPY $IWM $QQQ Huge News just look for yourself don't regret it $ENVB $ZSTK 👀 🔮🐦‍🔥
0 · Reply
Luckyjs38
Luckyjs38 Jan. 29 at 1:12 PM
$ENVB Huge news get ready for a massive run
0 · Reply
Love_To_Learn
Love_To_Learn Jan. 29 at 1:02 PM
$ENVB ME OFF 3.49
0 · Reply
stocktrade77
stocktrade77 Jan. 29 at 6:33 AM
$ENVB added here for a swing to 4 ish RDO VLOSED
0 · Reply
RBLUCKY
RBLUCKY Jan. 28 at 9:38 PM
$ENVB looks like they gotta pay those pricey salaries they’re getting.
0 · Reply
Mikeqb20
Mikeqb20 Jan. 28 at 8:42 PM
$ENVB #BUY @jacksparo @topstockalerts @IncredibleTrade
0 · Reply
VegasOracle
VegasOracle Jan. 28 at 8:21 PM
$ENVB BUY BUY BUY
0 · Reply
Mikeqb20
Mikeqb20 Jan. 28 at 8:08 PM
$ENVB Bought 7,500 $3.55 LFG MOFO'S @ACInvestorBlog @FonsieTrader
0 · Reply